Amylon is led by founder Thomas de Vlaam, a science entrepreneur who invented Amylon’s lead program AT-010. He developed the program at ProQR Therapeutics as their therapeutic area leader for CNS indications. Thomas holds an International Bachelor’s degree of Medicine and Global health from the University of Groningen.
Advisory board member
Thomas Wisniewski is the director of Alzheimer’s disease research Center at NYU School of medicine. Dr. Wisniewski obtained his medical degree at Kings College School of Medicine in the UK. He did his Neurology and Neuropathology Residencies at NYU and Columbia-Presbyterian, respectively. He is a board certified Neurologist and Neuropathologist, who runs an active research laboratory focusing on neurodegenerative disorders, which has led to over 210 peer-reviewed publications and has been continuously funded from the NIH and other Agencies such as the Alzheimer’s Disease Association for over 20 years.
Professor of Neurology at Harvard Medical School
Steve Greenberg. Dr. Greenberg, Professor of Neurology at Harvard Medical School, holds the John J. Conway Endowed Chair in Neurology, directs the Hemorrhagic Stroke Research Program, and is Vice-Chair for Faculty Development and Promotions at the Massachusetts General Hospital. Initiated in 1994, the Hemorrhagic Stroke Research Program has become internationally recognized as a leading authority on the causes, diagnosis, and treatment of cerebral amyloid angiopathy.
Supervisory board member
Dinko Valerio is a scientist and an experienced biotech entrepreneur with experience in both public and private companies as CEO and board member. Mr. Valerio is founder and former CEO of Crucell N.V., a Dutch biotech company, and founder and general partner of Aescap Venture, a life sciences venture capital firm. In 1999, Mr. Valerio was one of the founders of Galapagos Genomics N.V., a spinout from Crucell N.V. which develops novel mode of action medicines. Adding to his corporate experience, Mr. Valerio is a professor in the field of gene therapy of the hematopoietic system at the University of Leiden. He is an author on more than 100 articles in peer-reviewed journals and an inventor on 11 patent-families. He currently serves as the chairman of the board at ProQR Therapeutics.
Advisory board member
Philip Scheltens is director and founder of the Alzheimer Center VUmc Amsterdam. In 2011 he was also appointed scientific director at ‘Pearlstring Institute’ (Parelsnoer Instituut) and appointed member of ‘Royal Academy of Arts and Sciences’ (Koninklijke Academie van Kunsten en Wetenschappen). Under his supervision more than 50 theses appeared and there are more than 665 publications to his name. He is active in many fields and is the initiator of the ‘Deltaplan Dementia’ (Deltaplan Dementie)
Gerard Platenburg has served as the Chief Innovation Officer for ProQR since February 2014. Gerard is a co-founder of ProQR and also served as the sole member of its supervisory board between August 2012 and December 2013. Gerard has an extensive background in RNA modulation and orphan drug discovery and development and is in charge of our innovation unit. Gerard has more than twenty years of senior managerial experience, which he gained during his different operational and leadership roles in growing biotech companies.
Director, Nonclinical Development
Tsinatkeab (Tsinat) Hailu is a scientist with a background in protein folding and directed protein evolution. Tsinat holds a master’s degree in Molecular Cell Biology and Biological Chemistry from VU University Amsterdam. He was a Howard Hughes Medical Institute research scholar at the University of Michigan, Ann Arbor from 2009 to 2014 where he worked on developing in vivo models for studying protein folding. Tsinat joined ProQR Therapeutics in June 2015 as the lead scientist in the AT-010 project. He is responsible for overseeing the nonclinical development of AT-010.